StudyFinder
Search Results
1 Study Matches
Phase I Study of Carfilzomib in combination with Cyclophosphamide and Etoposide for Children with Relapsed or Refractory Solid Tumors and Leukemias
A study of the safety of carfilzomib for children with solid tumors and leukemias that returned or did not respond to previous treatment.
You will be expected to take your study drug combination and you will also need to come to all study visits as possible. Through the course of the study during your study visits, you will have periodic physical examinations, blood and urine tests, and scans or other tests, such as bone marrow aspirate/biopsy or cerebrospinal fluid collection, to assess your cancer. In the beginning of the study you will also have tests of your heart function (an ECG and echocardiogram). Some of these tests would have been done anyway for the routine care of your cancer, and some may be additional to that.
Suzanne Treadway, MS, RN, CCRP - at streadway@pennstatehealth.psu.edu or 717-531-3097
All
All
NCT02512926
STUDY00003127
Inclusion Criteria:
Diagnosis of relapsed or refractory solid tumor. Age 6 months to less than 30 years at enrollment.
Must be fully recovered from effects of previous treatment.
Life expectancy greater than or equal to 3 months.
Exclusion Criteria:
Prior treatment with carfilzomib.Known allergy to Captisol®.
Down syndrome.
Children's Health, Cancer